PERTUZUMAB,TRASTUZUMAB
Background and Date of Approval
Pertuzumab and trastuzumab is a targeted therapy containing the active constituents pertuzumab and trastuzumab. These were approved by the U.S. Food and Drug Administration (FDA) for treating HER2-positive breast cancer in combination with chemotherapy on June 8, 2012. Cancer occurs when cells begin to grow abnormally in an uncontrolled manner.
Uses
Pertuzumab, Trastuzumab, is used to treat breast cancer (human epidermal growth factor receptor 2 positive breast cancer) that has spread to other parts of the body (metastasized) or cancer that has come back after the treatment. It will also be given before or after the surgery if the cancer has not metastasized.
How is it administered?
Pertuzumab, Trastuzumab is a medication administered intravenously (IV) by a healthcare professional. It is important to follow the healthcare provider's instructions regarding the dosage and administration of medication. Refrain from doubling the dose to make up for missed doses.
Side Effects
Pertuzumab, Trastuzumab can cause several side effects, both common and serious. The most common side effects include fatigue, diarrhea, nausea, vomiting, and decreased appetite. These side effects are often mild to moderate and can be managed with supportive care. However, these can also cause more serious side effects like heart-related complications, infusion-related reactions, and immune-related adverse events.
Warnings
Pertuzumab, Trastuzumab carry important warnings, particularly regarding their potential to cause cardiac toxicity, which can lead to congestive heart failure, arrhythmias, and other cardiac complications. Other warnings include the potential to cause infusion-related reactions, lung toxicity, and fetal harm during pregnancy.
Precautions
Patients with a history of severe hypersensitivity reactions or anaphylactic shock should not receive Pertuzumab, Trastuzumab. It is also not recommended for use in patients with autoimmune disorders or those who are immunocompromised. Patients with a history of cardiac events, liver or kidney disease, or pulmonary embolism should be closely monitored during treatment. Patients should discuss these risks and benefits with their healthcare provider before starting treatment with pertuzumab and trastuzumab.
Word of Advice
Patients prescribed Pertuzumab, Trastuzumab, or other medications should carefully review the warnings and precautions relevant to their treatment. Monitoring for allergic reactions—including rash, itching, or swelling—is essential, and patients should seek immediate medical attention if these symptoms develop. Use with caution in patients with severe renal impairment. Inform your physician if you have a history of cardiac disease, prior radiotherapy, or allergic conditions. Effective contraception is necessary during treatment and for at least seven months following the final dose. Maintain adequate nutritional intake to support overall health during therapy.
References
Roche products limited, Electronic medicines compendium (EMC), [Revised on Jan 2022] [ Accessed on 03/05/2023], https://www.medicines.org.uk/emc/files/pil.11989.pdf zhu Chenjing et al.; Safety and efficacy evaluation of pertuzumab in patients with solid tumors; Medicine; [Published on May 2017]; [Accessed on 03/05/2023] https://journals.lww.com/md-journal/fulltext/2017/05190/safety_and_efficacy_evaluation_of_pertuzumab_in.19.aspx Sandra M Swain et al; Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer; The New England Journal of Medicine; [Published on Feb 2015]; [Accessed on 03/05/203]; https://pubmed.ncbi.nlm.nih.gov/25693012/
Frequently Asked Questions
Can Pertuzumab, Trastuzumab cause infertility?
Pertuzumab, Trastuzumab can affect fertility in some patients, although the extent of this effect is not well-understood. Women who wish to preserve their fertility should discuss their options with their healthcare provider before starting treatment with these drugs.
Can Pertuzumab, Trastuzumab be used together with chemotherapy?
Yes, Pertuzumab, Trastuzumab are often combined with chemotherapy to treat HER2-positive breast cancer. This combination therapy effectively reduces the risk of recurrence and improves overall survival in patients with HER2-positive breast cancer.
Can I take Pertuzumab, Trastuzumab if I have TB?
If you have active tuberculosis (TB) infection, Pertuzumab, Trastuzumab should only be used once the TB infection has been treated and is under control. These drugs can suppress the immune system, worsening TB or other infections.
Can Pertuzumab, Trastuzumab cause skin reactions?
Yes, Pertuzumab, Trastuzumab can cause skin reactions, including rash, dry skin, and itching. In some cases, these skin reactions can be severe and require treatment. Patients should promptly report any new or worsening skin symptoms to their healthcare provider.
Can Pertuzumab, Trastuzumab affect blood counts?
Yes, Pertuzumab, Trastuzumab can affect blood counts and may increase the risk of anemia, thrombocytopenia, and neutropenia. These blood disorders can cause symptoms such as fatigue, weakness, and an increased risk of infections or bleeding. Patients receiving this medication should check their blood counts regularly.
Can Pertuzumab, Trastuzumab be used in older adults?
Yes, Pertuzumab, Trastuzumab can be used in older adults. However, older adults may be at increased risk of side effects like heart-related complications or infections. Healthcare providers may need to adjust the dose or monitor more closely for potential side effects in older patients.
Can Pertuzumab, Trastuzumab be used in men with breast cancer?
Yes, Pertuzumab, Trastuzumab can be used in men with HER2-positive breast cancer. Breast cancer is rare in men, accounting for less than 1% of all breast cancer cases. However, HER2-positive breast cancer is more common in men than in women with breast cancer.